TESARO Inc (NASDAQ:TSRO) major shareholder Enterprise Associates 13 L. New purchased 54,642 shares of the company’s stock in a transaction dated Friday, March 2nd. The shares were acquired at an average price of $55.56 per share, for a total transaction of $3,035,909.52. Following the purchase, the insider now directly owns 252 shares of the company’s stock, valued at approximately $14,001.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of TESARO Inc (TSRO) traded down $1.91 during midday trading on Wednesday, hitting $62.69. The stock had a trading volume of 818,816 shares, compared to its average volume of 1,120,000. The company has a quick ratio of 4.39, a current ratio of 4.74 and a debt-to-equity ratio of 1.75. TESARO Inc has a 1-year low of $52.20 and a 1-year high of $171.80. The firm has a market cap of $3,410.00, a price-to-earnings ratio of -6.83 and a beta of 1.40.
TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.96). The firm had revenue of $48.02 million for the quarter, compared to analyst estimates of $51.78 million. TESARO had a negative return on equity of 126.44% and a negative net margin of 222.15%. sell-side analysts forecast that TESARO Inc will post -9.54 earnings per share for the current year.
TSRO has been the topic of several recent research reports. Citigroup restated a “buy” rating and issued a $135.00 price objective (down previously from $216.00) on shares of TESARO in a research report on Wednesday, December 20th. Morgan Stanley lowered their price objective on TESARO from $165.00 to $156.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 16th. HC Wainwright reaffirmed a “buy” rating and set a $158.00 target price on shares of TESARO in a research note on Friday, January 12th. Cowen reduced their target price on TESARO from $125.00 to $80.00 and set a “market perform” rating for the company in a research note on Tuesday, January 2nd. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $150.00 target price (down from $190.00) on shares of TESARO in a research note on Thursday, January 18th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $133.39.
Hedge funds have recently made changes to their positions in the business. Exane Derivatives grew its stake in shares of TESARO by 137.1% in the 4th quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 1,123 shares during the last quarter. Toronto Dominion Bank boosted its stake in shares of TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 1,130 shares in the last quarter. Bourgeon Capital Management LLC purchased a new stake in shares of TESARO in the fourth quarter valued at approximately $211,000. Fox Run Management L.L.C. purchased a new stake in shares of TESARO in the fourth quarter valued at approximately $218,000. Finally, Commonwealth Equity Services Inc purchased a new stake in shares of TESARO in the third quarter valued at approximately $222,000.
COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2018/03/15/tesaro-inc-tsro-major-shareholder-enterprise-associates-13-l-new-purchases-54642-shares.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.